Dexcom, Inc.
Thesis
Dexcom is facing significant challenges due to increasing competition from integrated devices that combine continuous glucose monitoring (CGM) technology with insulin pump therapy. The company's revenue growth is under pressure as customer acquisition costs rise and the market is not valuing the business based on earnings or cash flow, but rather on market opportunity. With the potential for pricing pressure and a saturated market, the stock is expected to decline.
Did it work?
No price performance data or pitch date is provided, so the core claim — that the stock would decline — cannot be verified against the pitch's entry point. Some thesis elements have plausibly materialized (intensifying CGM competition and growth deceleration at Dexcom have been widely reported), but without knowing when the pitch was made or the interim return, it is impossible to attribute outcomes to the thesis. Verdict is inconclusive with low confidence.